摘要
目的:探讨围术期应用左西孟旦治疗急性心肌梗死PCI术后患者高敏肌钙蛋白I、NT-proBNP、CRP指标的变化及临床意义。方法:选取2019年1月~2021年12月就诊于青岛市市立医院的92例患者作为研究对象,将所有患者随机分为两组:其中观察组46例(急诊PCI治疗 + 左西孟旦),对照组46例(单纯急诊PCI治疗),监测两组患者治疗前后高敏肌钙蛋白I、NT-proBNP、CRP指标的变化,并分析其临床意义。结果:治疗72 h及7天后,观察组患者在减轻高敏肌钙蛋白I、NT-proBNP、CRP等指标的持续上升优于对照组(P 【0.05)。结论:围术期应用左西孟旦可以有效减轻高敏肌钙蛋白I、NT-proBNP、CRP升高趋势。
Objective: To investigate the changes and clinical significance of hypersensitive troponin I, NT-proBNP and CRP in patients with acute myocardial infarction treated with levosimendan during perioperative period after PCI. Methods: 92 patients in Qingdao Municipal Hospital from January 2019 to December 2021 were selected as the research object. All patients were randomly divided into two groups: 46 cases in the observation group (emergency PCI + levosimendan) and 46 cases in the control group (emergency PCI only). The changes of high-sensitivity troponin I, NT-proBNP and CRP indexes before and after treatment were monitored, and its clinical significance was analyzed. Results: 72 hours and 7 days after treatment, the patients in the observation group reduced the continuous rise of high-sensitivity troponin I, NT-proBNP and CRP better than the control group (P <0.05). Conclusion: The perioperative application of levosimendan can effectively reduce the rising trend of high-sensitivity troponin I, NT-proBNP and CRP.
出处
《临床医学进展》
2022年第3期1574-1578,共5页
Advances in Clinical Medicine
